TheraRadar
← Back
Data updated: Mar 29, 2026

Novartis

NVS
OncologyCardiovascularImmunology
Big Pharma

Swiss pharma focused on innovative medicines and generics (Sandoz). Leading positions in oncology, ophthalmology, and cardiovascular. Major drugs include Entresto, Cosentyx, and Kisqali.

$50.3B
Revenue (2024)
$210.0B
Market Cap
-
Trials
2952
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 36%
33 drugs Phase 3: 47 Phase 2: 75 Phase 1: 121
Cardiovascular 21%
38 drugs Phase 3: 23 Phase 2: 18 Phase 1: 24
Immunology 17%
12 drugs Phase 3: 43 Phase 2: 18 Phase 1: 22
Ophthalmology 16%
20 drugs Phase 3: 30 Phase 2: 10 Phase 1: 23
Respiratory 10%
8 drugs Phase 3: 18 Phase 2: 29 Phase 1: 12

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...